In a report released today, Andy Hsieh from William Blair maintained a Hold rating on Nektar Therapeutics (NKTR – Research Report). The ...
Analysts at William Blair issued their Q1 2026 earnings estimates for Enovix in a report issued on Thursday, February 20th. William Blair analyst J. Dorsheimer expects that the company will earn ...
Stock analysts at William Blair lowered their Q1 2025 EPS estimates for shares of AMN Healthcare Services in a report issued ...
Fintel on MSN3d
William Blair Downgrades CACI International (CACI)Fintel reports that on February 21, 2025, William Blair downgraded their outlook for CACI International (NYSE:CACI) from ...
Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...
Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...
William Blair downgraded Booz Allen (BAH) to Market Perform from Outperform.Discover the Best Stocks and Maximize Your Portfolio: See what ...
Fintel reports that on February 21, 2025, William Blair downgraded their outlook for General Dynamics (WBAG:GEDY) from Outperform to Market Perform. There are 2,727 funds or institutions reporting ...
WJCC leaders will consider a potential name change for the school building on Longhill Road and, if approved, the ...
William Blair International Growth Fund earns an Average Process Pillar rating. The main driver of the rating is the fund's excellent long-term risk-adjusted performance. This can be seen in its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback